435 related articles for article (PubMed ID: 25795009)
1. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies.
Hatano T; Saiki S; Okuzumi A; Mohney RP; Hattori N
J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):295-301. PubMed ID: 25795009
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.
Luan H; Liu LF; Tang Z; Zhang M; Chua KK; Song JX; Mok VC; Li M; Cai Z
Sci Rep; 2015 Sep; 5():13888. PubMed ID: 26365159
[TBL] [Abstract][Full Text] [Related]
3. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
Han W; Sapkota S; Camicioli R; Dixon RA; Li L
Mov Disord; 2017 Dec; 32(12):1720-1728. PubMed ID: 28880465
[TBL] [Abstract][Full Text] [Related]
4. Potential biomarkers of Parkinson's disease revealed by plasma metabolic profiling.
Zhao H; Wang C; Zhao N; Li W; Yang Z; Liu X; Le W; Zhang X
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():101-108. PubMed ID: 29518718
[TBL] [Abstract][Full Text] [Related]
5. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.
Trupp M; Jonsson P; Ohrfelt A; Zetterberg H; Obudulu O; Malm L; Wuolikainen A; Linder J; Moritz T; Blennow K; Antti H; Forsgren L
J Parkinsons Dis; 2014; 4(3):549-60. PubMed ID: 24927756
[TBL] [Abstract][Full Text] [Related]
6. LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease.
Luan H; Liu LF; Meng N; Tang Z; Chua KK; Chen LL; Song JX; Mok VC; Xie LX; Li M; Cai Z
J Proteome Res; 2015 Jan; 14(1):467-78. PubMed ID: 25271123
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry.
Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W
Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385
[TBL] [Abstract][Full Text] [Related]
8. A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.
Troisi J; Landolfi A; Vitale C; Longo K; Cozzolino A; Squillante M; Savanelli MC; Barone P; Amboni M
Metabolomics; 2019 Jun; 15(6):90. PubMed ID: 31183578
[TBL] [Abstract][Full Text] [Related]
9. Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease.
Chang KH; Cheng ML; Tang HY; Huang CY; Wu YR; Chen CM
Mol Neurobiol; 2018 Aug; 55(8):6319-6328. PubMed ID: 29294246
[TBL] [Abstract][Full Text] [Related]
10. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.
Lewitt PA; Li J; Lu M; Beach TG; Adler CH; Guo L;
Mov Disord; 2013 Oct; 28(12):1653-60. PubMed ID: 23873789
[TBL] [Abstract][Full Text] [Related]
11. GC-MS Based Metabolic Profiling of Parkinson's Disease with Glutathione S-transferase M1 and T1 Polymorphism in Tunisian Patients.
Rebai A; Reçber T; Nemutlu E; Chbili C; Kurbanoglu S; Kir S; Amor SB; Özkan SA; Saguem S
Comb Chem High Throughput Screen; 2020; 23(10):1041-1048. PubMed ID: 32342808
[TBL] [Abstract][Full Text] [Related]
12. Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
Trezzi JP; Galozzi S; Jaeger C; Barkovits K; Brockmann K; Maetzler W; Berg D; Marcus K; Betsou F; Hiller K; Mollenhauer B
Mov Disord; 2017 Oct; 32(10):1401-1408. PubMed ID: 28843022
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics-based identification of metabolic alterations in PARK2.
Okuzumi A; Hatano T; Ueno SI; Ogawa T; Saiki S; Mori A; Koinuma T; Oji Y; Ishikawa KI; Fujimaki M; Sato S; Ramamoorthy S; Mohney RP; Hattori N
Ann Clin Transl Neurol; 2019 Mar; 6(3):525-536. PubMed ID: 30911576
[TBL] [Abstract][Full Text] [Related]
14. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects.
Wuolikainen A; Jonsson P; Ahnlund M; Antti H; Marklund SL; Moritz T; Forsgren L; Andersen PM; Trupp M
Mol Biosyst; 2016 Apr; 12(4):1287-98. PubMed ID: 26883206
[TBL] [Abstract][Full Text] [Related]
15. Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson's disease.
Ohmichi T; Kasai T; Kosaka T; Shikata K; Tatebe H; Ishii R; Shinomoto M; Mizuno T; Tokuda T
PLoS One; 2018; 13(7):e0201260. PubMed ID: 30044870
[TBL] [Abstract][Full Text] [Related]
16. Diagnosing Parkinson's disease and monitoring its progression: Biomarkers from combined GC-TOF MS and LC-MS/MS untargeted metabolomics.
Dahabiyeh LA; Nimer RM; Wells JD; Abu-Rish EY; Fiehn O
Heliyon; 2024 May; 10(9):e30452. PubMed ID: 38720721
[TBL] [Abstract][Full Text] [Related]
17. Lipid metabolic dysregulation is involved in Parkinson's disease dementia.
Dong MX; Wei YD; Hu L
Metab Brain Dis; 2021 Mar; 36(3):463-470. PubMed ID: 33433787
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease.
Glaab E; Trezzi JP; Greuel A; Jäger C; Hodak Z; Drzezga A; Timmermann L; Tittgemeyer M; Diederich NJ; Eggers C
Neurobiol Dis; 2019 Apr; 124():555-562. PubMed ID: 30639291
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic biomarkers as strong correlates of Parkinson disease progression.
LeWitt PA; Li J; Lu M; Guo L; Auinger P;
Neurology; 2017 Feb; 88(9):862-869. PubMed ID: 28179471
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
